These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15831599)

  • 41. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada.
    Brophy JM; Erickson LJ
    Int J Technol Assess Health Care; 2005; 21(3):326-33. PubMed ID: 16110712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost effectiveness analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery.
    Rao C; Aziz O; Panesar SS; Jones C; Morris S; Darzi A; Athanasiou T
    BMJ; 2007 Mar; 334(7594):621. PubMed ID: 17337457
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economics of sirolimus-eluting stents: drug-eluting stents have really arrived.
    Weintraub WS
    Circulation; 2004 Aug; 110(5):472-4. PubMed ID: 15289386
    [No Abstract]   [Full Text] [Related]  

  • 44. What reimbursement for coronary revascularization with drug-eluting stents?
    Tarricone R; Marchetti M; Lamotte M; Annemans L; de Jong P
    Eur J Health Econ; 2004 Dec; 5(4):309-16. PubMed ID: 15759170
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent.
    Greenberg D; Cohen DJ
    Z Kardiol; 2002; 91 Suppl 3():137-43. PubMed ID: 12641029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug eluting stents: maximising benefit and minimising cost.
    Gunn J; Morton AC; Wales C; Newman CM; Crossman DC; Cumberland DC
    Heart; 2003 Feb; 89(2):127-31. PubMed ID: 12527654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decision models for assessing the cost effectiveness of drug-eluting stents.
    Kong DF; Eisenstein EL
    Expert Opin Pharmacother; 2005 Jun; 6(6):965-74. PubMed ID: 15952924
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study.
    Griffin SC; Barber JA; Manca A; Sculpher MJ; Thompson SG; Buxton MJ; Hemingway H
    BMJ; 2007 Mar; 334(7594):624. PubMed ID: 17339236
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dollars and stents: the economics of drug-eluting stents.
    Wokhlu A; Jollis JG
    Am Heart Hosp J; 2005; 3(2):94-8, 104. PubMed ID: 15864023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug-eluting stents versus bare metal stents.
    Conti CR
    Clin Cardiol; 2003 Nov; 26(11):493-4. PubMed ID: 14640461
    [No Abstract]   [Full Text] [Related]  

  • 51. Hippocrates revisited: the evidence for drug-eluting stents.
    Kereiakes DJ
    Circulation; 2003 Jun; 107(24):3012-4. PubMed ID: 12821588
    [No Abstract]   [Full Text] [Related]  

  • 52. Treating multivessel disease in the era of coated stents: conclusion.
    Di Mario C; Griffiths H
    Heart; 2004 Sep; 90(9):1003. PubMed ID: 15310685
    [No Abstract]   [Full Text] [Related]  

  • 53. Wake up call for Dutch cardiologists.
    Serruys PW; Ong AT
    Neth Heart J; 2003 Oct; 11(10):405-411. PubMed ID: 25696150
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Some thoughts on the present and future of coronary artery stenting.
    De Feyter PJ; Ruygrok PN; Mills P
    Heart; 1996 Jun; 75(6):546-8. PubMed ID: 8697154
    [No Abstract]   [Full Text] [Related]  

  • 55. Frontal Sinus Drug-Eluting Implants-Effective, but for Which Patients and at What Cost?
    Gray ST; Sedaghat AR
    JAMA Otolaryngol Head Neck Surg; 2018 Jan; 144(1):35-36. PubMed ID: 29098295
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial.
    Vieira RD; Hueb W; Hlatky M; Favarato D; Rezende PC; Garzillo CL; Lima EG; Soares PR; Hueb AC; Pereira AC; Ramires JA; Kalil Filho R
    Circulation; 2012 Sep; 126(11 Suppl 1):S145-50. PubMed ID: 22965975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic evaluation of process utility: elucidating preferences for a non-invasive procedure to treat restenosis.
    Aviles-Blanco MV
    Health Econ Rev; 2021 Jul; 11(1):27. PubMed ID: 34297212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness analysis of the national implementation of integrated community case management and community-based health planning and services in Ghana for the treatment of malaria, diarrhoea and pneumonia.
    Escribano Ferrer B; Hansen KS; Gyapong M; Bruce J; Narh Bana SA; Narh CT; Allotey NK; Glover R; Azantilow NC; Bart-Plange C; Sagoe-Moses I; Webster J
    Malar J; 2017 Jul; 16(1):277. PubMed ID: 28679378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drivers of healthcare costs associated with the episode of care for surgical aortic valve replacement versus transcatheter aortic valve implantation.
    Wijeysundera HC; Li L; Braga V; Pazhaniappan N; Pardhan AM; Lian D; Leeksma A; Peterson B; Cohen EA; Forsey A; Kingsbury KJ
    Open Heart; 2016; 3(2):e000468. PubMed ID: 27621832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term Cost-Effectiveness of Diagnostic Tests for Assessing Stable Chest Pain: Modeled Analysis of Anatomical and Functional Strategies.
    Bertoldi EG; Stella SF; Rohde LE; Polanczyk CA
    Clin Cardiol; 2016 May; 39(5):249-56. PubMed ID: 27080921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.